Drug Profile

4D 110

Alternative Names: 4D-110; 4D-R110; RG 6247

Latest Information Update: 17 Jan 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 4D Molecular Therapeutics
Developer 4D Molecular Therapeutics; Roche
Class Eye disorder therapies; Gene therapies
Mechanism of Action Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Choroideraemia
New Molecular Entity No

Highest Development Phases

Discontinued Choroideraemia

Most Recent Events

10 Jan 2025 Discontinued - Phase-I for Choroideraemia in USA (Intravitreous)
02 Aug 2023 4D 110 is still in phase I trial for Choroideraemia in the US (4D Molecular Therapeutics pipeline, July 2023)
28 Jul 2023 No recent reports of development identified for phase-I development in Choroideraemia in USA (Intravitreous)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com